Delivery Order SPE2DB25D3201-SPE2DB25FNSJX
Award Date
4/14/25
Potential Completion Date
4/15/25
Potential Value
$6.2K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is between the U.S. Defense Logistics Agency (DLA) Troop Support Medical and Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $9,039.44, is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA. The IDC, worth up to $999,999,999.00, serves as the primary vehicle for Amerisourcebergen to supply a comprehensive range of...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,922.92, is a Firm Fixed Price Delivery Order for the supply of CATHFLO ACTIVASE 2 MG VIALS. The contract has an ultimate completion date of July 29, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,090.40, is for the delivery of 2 mg vials of Cathflo Activase, a medication used to treat certain blood clots. The contract has an ultimate completion date of April 11, 2025 and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,264.07, is for the delivery of the pharmaceutical product CATHFLO ACTIVASE 2 MG VIALS. The contract is a firm fixed-price delivery order with an ultimate completion date of December 27, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,679.87 delivery order contract is for the supply of CATHFLO ACTIVASE 2 MG VIALS, a pharmaceutical product. The award is not set aside and is a firm fixed-price contract type with a performance period ending on May 15, 2025. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery...
This federal contract award is for the delivery of Cathflo Activase 2 mg vials to the Defense Logistics Agency (DLA). The $9,044.45 Firm Fixed Price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract has an ultimate completion date of November 13, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which provides a...
This federal contract award is for the delivery of Cathflo Activase 2 mg vials, a pharmaceutical product, to the Defense Logistics Agency (DLA) Troop Support Medical. The prime contractor is Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has a ceiling value of $7,313.27 and an ultimate completion date of May 1, 2024. This is a delivery order contract with a firm fixed price pricing type. The contract is not designated with any set-aside requirements,...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,131.20, is for the delivery of CATHFLO ACTIVASE 2 MG VIALS, a medical product. The contract has a firm fixed price pricing type and an ultimate completion date of April 8, 2025. No set-aside designation was used for this award. AmerisourceBergen Drug Corp holds a significant Indefinite...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp for the supply of 4,565,778,830 units of the pharmaceutical product CATHFLO ACTIVASE 2 MG VIALS. The contract has a ceiling value of $9,654.84 and a period of performance through September 13, 2024. The contract is a firm-fixed-price delivery order, with no set-aside designation. Amerisourcebergen, a major pharmaceutical distributor, has been awarded this contract to provide critical...
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,393.60, is for the procurement of CATHFLO ACTIVASE 2 MG VIALS medical supplies. It is a Firm Fixed Price contract with a completion date of February 5, 2025. The contract is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the...